• Propanc Biopharma signed an MOU with Avance Clinical to support clinical delivery of its Phase 1b first-in-human trial of PRP.
• The trial targets patients with advanced solid tumors, with endpoints including safety, tolerability, pharmacokinetics, immunogenicity, and early activity.
• Parties plan to use the collaboration to accelerate PRP from first-in-human into proof-of-concept, subject to results.
• Avance Clinical will provide early-phase oncology CRO support, with the program expected to run through Australia’s faster ethics pathway and 43.5% R&D tax rebate.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607070830PRIMZONEFULLFEED9758120) on July 07, 2026, and is solely responsible for the information contained therein.